AR107018A2 - Composición de conjugado polisacárido neomocóccico multivalente-proteína - Google Patents

Composición de conjugado polisacárido neomocóccico multivalente-proteína

Info

Publication number
AR107018A2
AR107018A2 ARP160103764A ARP160103764A AR107018A2 AR 107018 A2 AR107018 A2 AR 107018A2 AR P160103764 A ARP160103764 A AR P160103764A AR P160103764 A ARP160103764 A AR P160103764A AR 107018 A2 AR107018 A2 AR 107018A2
Authority
AR
Argentina
Prior art keywords
immunogenic composition
protein
polysaccharides
crm197
vaccination
Prior art date
Application number
ARP160103764A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36709976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR107018(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR107018A2 publication Critical patent/AR107018A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Reivindicación 1: Una composición inmunogénica multivalente, que comprende: 13 conjugados polisacárido-proteína distintos, junto con un vehiculo fisiológicamente aceptable, donde cada uno de los conjugados comprende un polisacárido capsular de un serotipo diferente de Streptococcus pneumoniae conjugado a una proteína portadora y los polisacáridos capsulares se preparan con los serotipos 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F y 23F, donde la proteína transportadora es CRM₁₉₇ y donde la conjugación es efectuada por aminación reductiva. Reivindicación 3: La composición inmunogénica de acuerdo con la reivindicación 2, en la cual el adyuvante es un adyuvante a base de aluminio. Reivindicación 6: La composición inmunogénica de acuerdo a una cualquiera de las reivindicaciones 1 - 4 caracterizada porque es usada en vacunación. Reivindicación 8: La composición inmunogénica de acuerdo a una cualquiera de las reivindicaciones 1 - 4 para el uso en la vacunación de infantes y niños pequeños, donde el esquema de vacunación es a los 2, 4, 6 y 12 - 15 meses de edad. Reivindicación 9: La composición inmunogénica de acuerdo a una cualquiera de las reivindicaciones 1 - 4 para el uso en la vacunación de adolescentes y adultos. Reivindicación 10: Una jeringa de una sola dosis llena con una formulación líquida de polisacáridos capsulares de Streptococcus pneumoniae de los serotipos 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F y 23F individualmente conjugados a CRM₁₉₇, donde cada dosis de 0,5 ml es formulada para contener 2,2 mg de cada sacárido, excepto 6B que es de 4 mg, aproximadamente 29 mg de la proteína portadora CRM₁₉₇, 0,125 mg de adyuvante de aluminio elemental (0,5 mg de fosfato de aluminio) y buffer de cloruro de sodio y succinato de sodio como excipientes. Reivindicación 13: Un proceso para preparar una composición inmunogénica multivalente, que comprende 13 conjugados polisacárido-proteína distintos, junto con un vehículo fisiológicamente aceptable, donde cada uno de los conjugados comprende un polisacárido capsular diferente conjugado a una proteína portadora CMR₁₉₇, donde: los polisacáridos capsulares son preparados desde los serotipos 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F y 23F de Streptococcus pneumoniae, los polisacáridos individuales son purificados a través de centrifugación, precipitación, ultrafiltración y columnas de cromatografía; los polisacáridos purificados están químicamente activados para hacer sacáridos capaces de reaccionar con la proteína transportadora CMR₁₉₇; una vez activados, cada polisacárido capsular es conjugado de manera individual con la proteína transportadora CRM₁₉₇ para formar un glicoconjugado; los glicoconjugados individuales están purificados y compuestos para formular la composición inmunogénica.
ARP160103764A 2005-04-08 2016-12-07 Composición de conjugado polisacárido neomocóccico multivalente-proteína AR107018A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66960505P 2005-04-08 2005-04-08

Publications (1)

Publication Number Publication Date
AR107018A2 true AR107018A2 (es) 2018-03-14

Family

ID=36709976

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101395A AR053354A1 (es) 2005-04-08 2006-04-07 Composicion de conjugado polisacarido neumococcico multivalente -proteina
ARP160103764A AR107018A2 (es) 2005-04-08 2016-12-07 Composición de conjugado polisacárido neomocóccico multivalente-proteína

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060101395A AR053354A1 (es) 2005-04-08 2006-04-07 Composicion de conjugado polisacarido neumococcico multivalente -proteina

Country Status (29)

Country Link
US (9) US20060228380A1 (es)
EP (9) EP2425853A1 (es)
JP (3) JP4472770B2 (es)
KR (11) KR101730749B1 (es)
CN (6) CN113198012B (es)
AR (2) AR053354A1 (es)
AT (1) ATE548051T1 (es)
AU (1) AU2006235013B2 (es)
BR (1) BRPI0607025B8 (es)
CA (4) CA2878579C (es)
CL (2) CL2016000566A1 (es)
CY (1) CY1112777T1 (es)
DK (1) DK1868645T3 (es)
ES (1) ES2382048T3 (es)
HK (1) HK1213184A1 (es)
HR (1) HRP20120278T1 (es)
IL (5) IL308456A (es)
ME (1) ME01334B (es)
MX (3) MX2007012336A (es)
MY (1) MY145150A (es)
NZ (1) NZ562406A (es)
PL (1) PL1868645T3 (es)
PT (1) PT1868645E (es)
RS (1) RS52249B (es)
SA (1) SA06270323B1 (es)
SI (1) SI1868645T1 (es)
TW (3) TWI386222B (es)
WO (1) WO2006110381A1 (es)
ZA (1) ZA200709483B (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620460B8 (pt) * 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
AU2012216628B9 (en) * 2006-04-26 2021-10-21 Wyeth Llc Novel Formulations which Stabilize and Inhibit Precipitation of Immunogenic Compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
DK2129693T3 (en) * 2007-03-23 2017-02-13 Wyeth Llc BRIEF PURIFICATION PROCEDURE FOR THE PREPARATION OF STREPTOCOCCUS PNEUMONIAE-Capsule POLYACCHARIDES
EP2155244B1 (en) * 2007-04-23 2017-03-22 Serum Institute of India Private Limited Antigenic polysaccharides and process for their preparation
EA201490303A1 (ru) * 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
ES2749952T3 (es) * 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
DK2379734T3 (en) * 2008-12-18 2018-04-23 Wyeth Llc Method for Controlling the Molecular Weight of Polysaccharide of Streptococcus Pneumoniae Serotype 19A
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
PT3170508T (pt) 2010-06-04 2020-01-16 Wyeth Llc Formulações de vacinas
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
KR101315599B1 (ko) * 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
AU2011384634A1 (en) 2011-12-29 2014-06-19 Novartis Ag Adjuvanted combinations of meningococcal factor H binding proteins
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
DK3421051T3 (da) 2012-08-16 2020-06-22 Pfizer Fremgangsmåder til glycokonjugering og sammensætninger
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
MX363051B (es) 2012-09-07 2019-03-06 Sk Bioscience Co Ltd Metodo para producir un polisacárido capsular con un serotipo de neumococo.
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104151426A (zh) * 2013-05-14 2014-11-19 北京天成新脉生物技术有限公司 肺炎链球菌十三种荚膜多糖单克隆抗体及其应用
CN103495161B (zh) * 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
DK3313436T3 (da) 2015-06-23 2021-03-08 Biological E Ltd Multivalent pneumokok-konjugatvaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US10159728B2 (en) * 2015-09-10 2018-12-25 Inventprise, Llc Multivalent VLP conjugates
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
SG11201900794PA (en) * 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
KR101991457B1 (ko) * 2016-09-06 2019-09-30 주식회사 엘지화학 다가 협막 다당류-운반 단백질을 포함하는 조성물 및 이의 용도
PH12019500672B1 (en) * 2016-09-30 2024-02-23 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
KR20240169144A (ko) 2017-01-31 2024-12-02 머크 샤프 앤드 돔 엘엘씨 다당류-단백질 접합체 제조 방법
US20200222550A1 (en) * 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018144799A1 (en) 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
KR102701633B1 (ko) 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
KR20190121330A (ko) 2017-02-24 2019-10-25 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
KR20240018698A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
AU2018328040B2 (en) * 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
CA3074706A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
EP3691677A4 (en) * 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
WO2019220304A1 (en) * 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
DK3817775T3 (da) 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
IL281204B2 (en) * 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
WO2020075201A1 (en) * 2018-10-12 2020-04-16 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN110302375A (zh) * 2019-06-27 2019-10-08 康希诺生物股份公司 一种糖缀合物及其用途
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
CN112741901B (zh) * 2019-10-31 2024-05-10 北京科兴中维生物技术有限公司 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法
MX2022005252A (es) 2019-11-01 2022-06-08 Pfizer Composiciones de escherichia coli y metodos de las mismas.
EP4065162A1 (en) * 2019-11-29 2022-10-05 Lonza Ltd Method of purifying polysaccharides
KR20220146451A (ko) * 2020-01-17 2022-11-01 인벤트프라이즈 엘엘씨 다가 스트렙토코커스 백신
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
EP4150104A1 (en) * 2020-05-14 2023-03-22 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
EP4192499A4 (en) 2020-08-10 2024-09-25 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR102610292B1 (ko) * 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko) 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
CN114106210A (zh) * 2021-11-09 2022-03-01 北京智飞绿竹生物制药有限公司 一种23价肺炎球菌多糖疫苗的生产工艺
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
CA3267399A1 (en) 2022-09-19 2024-03-28 Biological E Limited PROCESS FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
TW202532099A (zh) 2024-02-14 2025-08-16 美商默沙東有限責任公司 肺炎鏈球菌結合物疫苗及其使用方法
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37741A (en) 1863-02-24 Improvement in bee-hives
US4097666A (en) 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
CA1115210A (en) 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FI914241A7 (fi) 1989-03-09 1991-09-09 Praxis Biologics Inc Rokotteita ei-tyypitettävää Haemophilus influenzae-bakteereja vastaan
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US5714354A (en) 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AU729684B2 (en) 1996-07-26 2001-02-08 Wyeth Holdings Corporation The NucA protein of Haemophilus influenzae and the gene encoding that protein
AU746442B2 (en) 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
DE69835522T2 (de) 1997-01-31 2007-03-01 Wyeth Holdings Corp. Das 74 kilodalton protein der äusseren membran von moraxella catarrhalis
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
CA2316975C (en) * 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
EP1053015A2 (en) * 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
BR9914066A (pt) 1998-09-24 2002-04-23 Univ Minnesota Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
JP2002539273A (ja) * 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
ES2343304T3 (es) 1999-06-25 2010-07-28 Wyeth Holdings Corporation Produccion de la forma lipidada de las lipoproteinas asociadas a peptidoglicano de bacterias gram-negativas.
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
DK1296715T4 (en) 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
WO2002048029A1 (en) 2000-12-13 2002-06-20 Sca Hygiene Products Zeist B.V. Recovery process for spent periodate
US7118756B2 (en) 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2473883A1 (en) 2001-11-29 2003-06-12 Wyeth Holdings Corporation Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
MXPA04008890A (es) 2002-03-15 2005-10-18 Wyeth Corp Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
WO2003094961A1 (en) 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
AU2003270779A1 (en) 2002-09-20 2004-04-08 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
BRPI0409459A (pt) 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
CN1241937C (zh) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 多价肺炎球菌多糖结合疫苗
CA2844154C (en) 2003-08-06 2016-12-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
DE602004025951D1 (de) 2003-09-11 2010-04-22 Staat Der Nederlanden Vert Doo Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat-impfstoffen
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
UA93854C2 (ru) 2003-12-17 2011-03-25 Вайет Ллк Иммуногенный конъюгат и способ его получения
US20060022838A1 (en) 2004-07-27 2006-02-02 Fisher Richard A Speed limit indicia for traffic signals
EP2425853A1 (en) * 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
KR101617464B1 (ko) 2006-09-29 2016-05-02 잇판사이단호진한다이비세이부쯔뵤우겐큐우카이 Ｉｐｖ―ｄｐｔ 백신
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
KR20190121330A (ko) * 2017-02-24 2019-10-25 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진

Also Published As

Publication number Publication date
EP2425856A1 (en) 2012-03-07
KR101298053B1 (ko) 2013-08-20
EP1868645A1 (en) 2007-12-26
IL186367A0 (en) 2008-01-20
KR102611449B1 (ko) 2023-12-06
KR20210022768A (ko) 2021-03-03
TWI445545B (zh) 2014-07-21
KR20220042483A (ko) 2022-04-05
KR20070118700A (ko) 2007-12-17
US8895024B2 (en) 2014-11-25
CL2016000566A1 (es) 2016-10-28
HK1213184A1 (zh) 2016-06-30
CA2604363A1 (en) 2006-10-19
KR101730750B1 (ko) 2017-04-26
EP2425854A1 (en) 2012-03-07
CN113198013B (zh) 2024-02-20
RS52249B (sr) 2012-10-31
ME01334B (me) 2013-12-20
US9981035B2 (en) 2018-05-29
JP5730261B2 (ja) 2015-06-03
EP2425852A1 (en) 2012-03-07
IL267125A (en) 2019-08-29
EP2425853A1 (en) 2012-03-07
IL186367A (en) 2013-09-30
MY145150A (en) 2011-12-30
SI1868645T1 (sl) 2012-04-30
SA06270323B1 (ar) 2010-10-05
TWI511739B (zh) 2015-12-11
JP2009161567A (ja) 2009-07-23
US20180250390A1 (en) 2018-09-06
AU2006235013B2 (en) 2011-11-03
CN113198012A (zh) 2021-08-03
CA2878579A1 (en) 2006-10-19
US20200179508A1 (en) 2020-06-11
KR102220506B1 (ko) 2021-03-02
TWI386222B (zh) 2013-02-21
TW201438734A (zh) 2014-10-16
IL308456A (en) 2024-01-01
CY1112777T1 (el) 2016-02-10
IL228035A0 (en) 2013-09-30
TW201212937A (en) 2012-04-01
NZ562406A (en) 2009-09-25
US11191830B2 (en) 2021-12-07
CA2986862A1 (en) 2006-10-19
KR101730748B1 (ko) 2017-04-26
PL1868645T3 (pl) 2012-07-31
CL2017002206A1 (es) 2018-03-23
KR102564388B1 (ko) 2023-08-08
US20140314805A1 (en) 2014-10-23
ATE548051T1 (de) 2012-03-15
US10780160B2 (en) 2020-09-22
PT1868645E (pt) 2012-05-17
US8808708B2 (en) 2014-08-19
JP4472770B2 (ja) 2010-06-02
CN108404126B (zh) 2022-10-18
KR20150061021A (ko) 2015-06-03
CN102716480A (zh) 2012-10-10
KR102378962B1 (ko) 2022-03-28
KR20130048262A (ko) 2013-05-09
KR20150061019A (ko) 2015-06-03
CN104815327A (zh) 2015-08-05
KR101588939B1 (ko) 2016-01-26
EP4005595A1 (en) 2022-06-01
CN101180079B (zh) 2012-07-18
EP1868645B1 (en) 2012-03-07
CA2986862C (en) 2022-09-27
EP2425851A1 (en) 2012-03-07
MX2007012336A (es) 2007-11-21
US20210283247A1 (en) 2021-09-16
KR101730749B1 (ko) 2017-04-26
US20160158345A1 (en) 2016-06-09
KR20190104241A (ko) 2019-09-06
MX2019008863A (es) 2019-09-13
ES2382048T3 (es) 2012-06-04
JP5173920B2 (ja) 2013-04-03
CN108404126A (zh) 2018-08-17
JP2013006881A (ja) 2013-01-10
BRPI0607025A2 (pt) 2009-07-28
US10716848B2 (en) 2020-07-21
EP2425855A1 (en) 2012-03-07
US20090130137A1 (en) 2009-05-21
KR102017842B1 (ko) 2019-09-03
US20190388537A1 (en) 2019-12-26
BRPI0607025B8 (pt) 2021-05-25
CN101180079A (zh) 2008-05-14
KR20150061020A (ko) 2015-06-03
BRPI0607025B1 (pt) 2019-11-12
TW200719911A (en) 2007-06-01
US9399060B2 (en) 2016-07-26
JP2008535838A (ja) 2008-09-04
WO2006110381A1 (en) 2006-10-19
CA2878579C (en) 2018-01-23
IL282638A (en) 2021-06-30
ZA200709483B (en) 2009-03-25
HRP20120278T1 (hr) 2012-04-30
CN113198013A (zh) 2021-08-03
CA3165042A1 (en) 2006-10-19
IL267125B (en) 2021-05-31
EP3311836A1 (en) 2018-04-25
CN102716480B (zh) 2023-03-21
HK1257962A1 (zh) 2019-11-01
US20060228380A1 (en) 2006-10-12
CA2604363C (en) 2015-06-16
AU2006235013A1 (en) 2006-10-19
KR20170086139A (ko) 2017-07-25
KR20230118200A (ko) 2023-08-10
US20120237542A1 (en) 2012-09-20
CN113198012B (zh) 2024-09-17
DK1868645T3 (da) 2012-04-10
AR053354A1 (es) 2007-05-02
KR20150061018A (ko) 2015-06-03
MX358148B (es) 2018-08-07
HK1120416A1 (en) 2009-04-03

Similar Documents

Publication Publication Date Title
ES3048958T3 (en) Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
ES3050314T3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
ES2883343T3 (es) Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
AR053354A1 (es) Composicion de conjugado polisacarido neumococcico multivalente -proteina
US11147863B2 (en) Multivalent pneumococcal conjugate vaccine
MX2009006547A (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
NO20082647L (no) Vaksine
AR066376A1 (es) Vacuna
RU2012138368A (ru) 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
ES2974992T3 (es) Vacuna contra Neisseria meningitidis
BRPI0721136A8 (pt) conjugado imunogênico, polissacarídeos de streptococcus pneumoniae sorotipo 1, composição imunogênica multivalente e seus métodos de produção
FI3244917T3 (fi) Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
HRP20190198T4 (hr) Formulacije koje stabiliziraju i inhibiraju taloženje imunogenih pripravaka
JP2008535838A5 (es)
JP2020525495A (ja) 新規の多価多糖類・タンパク質のコンジュゲートワクチン組成物及びその製剤
Wilck et al. Protective immune responses against Haemophilus influenzae type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™)
Wu et al. Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm
BRPI0013686B1 (pt) procedimento para sintetizar uma mistura de oligossacarídeos
Eskola et al. New vaccines for prevention of pneumococcal infections
TH74129B (th) สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต
TH171459A (th) องค์ประกอบมัลติวาเลนท์ นิวโมคอกคัสโพลีแซคคาไรด์-โปรตีน คอนจูเกต
RU2022110368A (ru) Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
TH108545A (th) สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต
TH1901001980A (th) องค์ประกอบนิวโมคอคคัลวัคซีนมัลติวาเลนท์ที่ประกอบรวมด้วยโพลีแซคคาไรด์-โปรตีนคอนจูเกต

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal